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Abstract. Background: Following an upward trajectory in Lymphogranuloma venereum (LGV) diagnoses in the UK
from 2004 to 2016, with annual diagnoses increasing from 28 to 904, diagnoses fell to 641 in 2017; this was inconsistent
with the upward trend in other bacterial sexually transmissible infections (STIs) between 2016 and 2017. An analysis of
surveillance data from multiple sources to investigate the possible factors contributing to this decline in LGV was
performed. Methods: LGV tests and diagnoses in the UK from 2004 to 2018 were captured through laboratory data
from the LGV Reference Laboratories and laboratories conducting in-house LGV testing. These data and clinical
diagnoses data from England were analysed alongside the national management guidelines issued over the course of the
epidemic. Results: LGV diagnoses increased between 2004 and 2015 and then decreased between 2016 and 2018. LGV
testing increased from 2010 to 2018 (2690–10 850). Test positivity halved between 2015 (14.8%, 929–6272) and 2018
(7.3%, 791–10 850). Peaks in LGV testing and diagnoses appeared to coincide with the publication of national LGV
management guidelines and changes to clinical practice. The proportion of LGV diagnoses among HIV-positive men
who have sex with men (MSM) fell between 2013 and 2018 (74–48%). Conclusions: The fall in diagnoses and
positivity were likely due to increasing earlier clinical diagnosis and treatment. Changes to the national management
guidelines, the clinical policy and practice of some larger clinics and potentially changes to the guidelines for the
treatment of chlamydia broadened the scope of testing and increased testing in asymptomatic patients which, in
combination, likely had a positive effect on the control of LGV infection.
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Introduction
Lymphogranuloma venereum (LGV) is a sexually transmissible
infection (STI) caused by the invasive L1, L2 and L3 serovars of
Chlamydia trachomatis.1 Increases in LGV were first seen
among gay, bisexual and other men who have sex with men
(MSM) in Western Europe in 2003, and outbreaks were
subsequently reported in other high-income countries,
including Australia.2 Diagnoses in the UK and across Europe
rose between 2004 and 2016, with the highest European rates
seen in the UK.3 Surveillance of LGV in the UK showed a
consistent ongoing pattern of the infection being concentrated in
MSM living in London, many of whom were co-infected HIV
and other STIs. Acquisition was associated with reported
behaviours such as condomless anal intercourse; fisting and
the use of sex toys; and the increased use of chemsex drugs and
group sex facilitated by geospatial networking applications.4–9
The increase in LGV diagnoses seen between 2009 and 2016
was consistent with trends of other STIs in England. Diagnoses
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of chlamydia, syphilis and gonorrhoea seen in those attending
sexual health services increased by 26%, 178% and 280%
respectively and, among MSM, by 338%, 234% and 642%
respectively.10
National UK LGV management guidelines have evolved
over the course of the epidemic in response to increased insight
into the burden of asymptomatic infection, clinical
presentation and groups at risk of infection. The initial test
for C. trachomatis offered at sexual health services does not
distinguish serovars D–K from LGV serovars (L1, L2 and L3).
The 2006 LGV guidelines recommended that testing for LGV
serovars should be performed on clinical suspicion based on
the presence of rectal symptoms and after the exclusion of
other aetiologies of rectal bleeding.11 The 2010 UK national
chlamydia management guidelines recommended that LGV
testing should only be offered to MSM who testing positive for
C. trachomatis at the rectal site and those presenting with any
rectal symptoms, together with the contacts of confirmed LGV
cases (Fig. 1).12 In 2013, the UK national LGV management
guidelines extended the testing of LGV to include testing
all MSM who test a positive for rectal or pharyngeal
C. trachomatis and those who present with rectal symptoms
consistent with LGV.13 Results of a 2012 case-finding study
showed that 27% of LGV infections were seen in patients
without rectal symptoms, indicating that the burden of
infection and the level of ongoing transmission may have
been higher than previously recognised.14 Consequently,
scope for LGV testing was extended in the 2015 chlamydia
guidelines. These guidelines recommended that, alongside
testing patients with signs and symptoms consistent with
LGV infection, LGV testing was conducted on samples
from all MSM living with HIV who test positive for
C. trachomatis at any site (rectal, genital or pharyngeal),
regardless of the presence of symptoms consistent with
LGV.15
After a consistent upward trajectory, a reduction in LGV
diagnoses in the UK was seen from the end of 2015 to 2018.
This divergence from the continued, sustained increases in
non-LGV chlamydia, syphilis and gonorrhoea in England was
assessed by Public Health England (PHE). Here, we present
the findings of this investigation, which considered the
influence of variations in testing guidelines and practices;
clinical and prescribing practices; and the test performance
of the diagnostic assay on the course of the epidemic and the
control of LGV in the UK.
Methods
Data sources
In the UK, LGV surveillance is coordinated by PHE using four
laboratory data sources that conduct LGC testing using the
same assay: (1) the PHE National Reference Laboratory,
which has performed LGV testing for all sexual health
clinics in England, Wales and Northern Ireland since 2004;
(2) three London hospital laboratories, which began providing
in-house LGV testing to some London sexual health clinics
from 2015 to 2018; (3) the Scottish Bacterial Sexually
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Fig. 1. Trends in Lymphogranuloma venereum (LGV) testing and diagnoses in males and females by year and quarter within the context
of chlamydia and LGV national management guidelines, UK: 2004–18.12,13,15
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performs LGV testing for all sexual health clinics in Scotland;
and (4) laboratory data from two of the health and social care
trusts in Northern Ireland, which began providing in-house
LGV testing to some sexual health clinics in 2018. Laboratory
data, which are collected quarterly from primary diagnostic
laboratories through the Chlamydia Testing Activity Dataset
surveillance system,16 provided both denominator (number of
LGV tests done) and numerator (number of positive tests) data.
Since 2009, all English-commissioned sexual health
services had a mandatory responsibility to return data to
PHE through the clinical coding-based GUMCAD STI
Surveillance System.17 A code for LGV diagnosis was
introduced in 2011. Due to underreporting of clinical
diagnoses as a result of the sequence of testing for LGV
following a positive non-LGV chlamydia result, ~70% of
LGV diagnoses captured in the laboratory data are reported
through GUMCAD. This dataset includes information on
patient characteristics, diagnoses of other STIs and services
provided, but does not capture data on LGV tests conducted.
Data analysis
To monitor the trends in both LGV tests performed and
diagnoses made, the UK laboratory data were de-duplicated
and combined to provide an accurate measure of the number of
individuals tested and diagnoses made by excluding instances
where individuals were tested for LGV twice within a 6-week
window. This was in line with the data cleaning performed on
clinical data.18
Laboratory testing data from 2004 to 2018 were
descriptively analysed to assess the long-term trends in LGV
diagnoses. Annual test positivity (number of diagnoses/total
tests, expressed as a percentage) was calculated for each country
in the UK and for each PHE Centre in England, and was
descriptively analysed alongside the number of annual tests
performed and number of tests that were positive for LGV.
The number of LGV tests performed and number of
positive tests were also calculated for each quarter and
stratified by gender. These data were descriptively analysed
alongside the relevant management guidelines that were
introduced between 2004 and 2018. LGV test positivity per
quarter was also calculated and descriptively analysed
alongside relevant guideline changes and changes in
prescribing and testing practices within large London-based
clinics with a high throughput of MSM. Clinical diagnoses
data from the GUMCAD STI Surveillance Systems were used
to inform the changing trends in diagnoses by sexual
orientation and HIV status; information that is not available
via laboratory data.
All data cleaning, collating and statistical analyses were
carried out used STATA 15.1 (College Station, TX, USA).
Investigating the performance of the diagnostic assay
The real-time–polymerase chain reaction (RT–PCR) assay
used for LGV diagnoses at the PHE National Reference
Laboratory was investigated to determine whether the
decrease in the number of LGV-positive specimens was due
to a reduction in assay sensitivity.19–21 ompA genotyping19 was
performed on 40 clinical specimens, accounting for
approximately one-third of samples sent to the reference
laboratory during the investigation period. Twenty clinical
specimens that were chlamydia positive/LGV negative were
selected at random from a routine PCR run and 20 clinical
specimens were from individuals who had clinical signs of
LGV infection and were positive for chlamydia, but were PCR
negative for LGV.
Ethical approval
Ethical approval was not required as collection and analysis of
LGV laboratory testing data were conducted as part of routine
national surveillance by PHE.22 Clinical data were obtained
from the GUMCAD STI Surveillance System, the mandatory
surveillance system for STIs in England. Public Health
England collects pseudo-anonymised, electronic data on all
STI tests and diagnoses from all commissioned sexual health
services in England.17,23
Results
National trends in LGV testing and diagnoses are presented
within the context of changes to national management
guidelines (Fig. 1).12,13,15 A further detailed view of trends
in LGV testing and positivity from 2006 to 2018 is presented
within the context of local clinical practice and national
management guidelines (Fig. 2).15,24,25 The geographic
distribution of LGV diagnoses, tests and positivity from
2004 to 2018 across the UK is shown in Table 1.
Trends in diagnoses
Between 2004 and 2016, annual diagnoses of LGV in the UK
rose from 28 to 904, with 99% of this 32-fold increase seen
among males (Fig. 1). Diagnoses in males peaked at 280 in Q1
2016 before decreasing by 53% to 129 in Q4 2017. Despite a
slight upturn in diagnoses since the start of 2018, overall
diagnoses were 26% lower in Q4 2018 (206) than at the
peak in 2016. The distribution of diagnoses by gender
changed little over this period, with a total of 24 LGV
diagnoses made among females between 2004 and 2018, 20
of which, were made after 2011.
Trends in testing
Across all UK countries, the number of LGV tests began to
increase gradually from 2010. Peaks in testing were seen at the
end of both 2012 and 2015, and testing was at its highest level
throughout 2017 and 2018 (Fig. 2). Testing was consistently
much higher among men (Fig. 1), but LGV testing among
females increased rapidly from 159 in 2010 to 1042 in 2017 and
then fell to 792 in 2018. A 21% decline in overall testing was
seen in 2017 (2266 in Q1, 1800 in Q4).
The annual positivity of LGV tests in the UK fluctuated
between 2006 and 2018, peaking at 18% in 2010 and 14% in
2014 (Fig. 2). Alongside an increase in testing, the proportion of
total tests that were positive halved between 2015 (14%) and
2018 (7%).
Changes in guidelines and clinical practice
Peaks in LGV testing and diagnoses appear to coincide with
the publication of revised national management guidelines
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concerning LGV testing and changes to clinical practice
(Figs 1, 2). From 2010 to 2011, the annual number LGV
tests increased by 14% (2690 to 3065), after modifications to
the chlamydia guidelines in 2010.12 Following the publication
of LGV guidelines in 2013, testing increased 28% (3742 to
4809) between 2013 and 2014; a 16% increase (6772 to 7885)
in testing was seen between 2015 and 2016 after the 2015
chlamydia guidelines were published and testing practices
were changed at two large London clinics; and a 29%
increase (8396 to 10 850) was seen between 2017 and 2018
after a third large London clinic changed its testing
practice.13,15 Additionally, the publication of the 2016
MSM guidelines, which recommend quarterly STI screening
of high-risk MSM, are likely to have contributed to the
national increase in LGV tests performed.25
Geographic variation
Between 2004 and 2018, the majority of LGV diagnoses were
made in London (4477/6637, 67%), followed by the North
West (602 diagnoses, 9.4%) and the South East
(468 diagnoses, 7%) (Table 1).
Lower numbers of diagnoses were reported in Wales
(44 diagnoses), Scotland (202) and Northern Ireland (31).
Both Scotland and Northern Ireland had a similar trend to
England (Table 1). Diagnoses increased in Scotland from 10 to
45 between 2010 and 2015 and then fell to 30 in 2018. In
Northern Ireland, diagnoses increased from two to eight from
2010 to 2016 and fell to four annual diagnoses in 2017
(Table 1). Reductions in positivity from 2015 that reflect
the national trend were seen in Wales and most PHE
centres within England (excluding the East Midlands and
East of England) (Table 1).
Patient characteristics
Analysis of clinical data submitted via the GUMCAD STI
Surveillance System shows that between 2013 and 2018, the
proportion of annual LGV diagnoses in England made among
MSM increased from 90% to 96%. Over the same period, the
proportion of MSM diagnosed with LGV who were living with
HIV fell from 74% to 48%, with the biggest year-to-year
decrease seen between 2016 and 2017 (67–59%).
Performance of the diagnostic assay
An investigation at PHE of the RT–PCR assay used for LGV
diagnoses showed that all ompA genotyping results were
concordant with the results of the RT–PCR assay used for
routine testing.
Discussion
After a sustained increase in diagnoses, the LGV epidemic
changed trajectory between 2015 and 2017. This fall, which was
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Chlamydia management guidelines updated: first line treatment
switched from Azithromycin to Doxycycline
A third large London clinic began testing asymptomatic patients
regardless of HIV status
National guidelines on the sexual health care of men who have sex with men published
recommending quarterly sexually trasmissible infection screening of high-risk MSM
Two large London clinics began testing asymptomatic patients
regardless of HIV status
Asymptomatic testing of HIV+ GBMSM with positive Chlamydia
trachomatis added to BASHH chlamydia management guidelines
Fig. 2. Trends in Lymphogranuloma venereum (LGV) testing and positivity by year and quarter within the context of local clinical practice and
national management guidelines, UK: 2006–18.15,24,25




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































348 Sexual Health H. Allen et al.
explained in terms of a decline in testing or under-reporting of
LGV diagnoses. In addition, it is unlikely the diagnostic assay
missed the LGV target due to an escape mutant. Rather, the
decreases in LGV diagnoses are likely related to changes in the
LGV and chlamydia national guidelines, suggested through
peaks in tests and diagnoses occurring within a year of the
publication of new guidelines. The observed increase in testing
may have led to the earlier clinical diagnosis, resulting in a
shorter infectious period and therefore reduced transmission of
LGV and the subsequent reduction in both diagnoses and
positivity since 2016.
The lack of available information concerning the extent to
which clinics adhered to national management guidelines,
specifically, the absence of data on clinical presentation,
LGV treatment regimens and testing coverage within
specific risk groups and data on the performance of partner
notification and management of contacts, has limited the
understanding of the course of the epidemic. Despite this,
both clinical and laboratory diagnostic and testing data
allowed a comprehensive assessment of LGV trends
together with sexual risk and demographic characteristics.
Additionally, an investigation of the RT–PCR assay showed
that the performance of the diagnostic test was as expected. It
should be noted that the assay was only investigated at PHE, so
some other escape mutants may have been missed in other
centres. This is, however, unlikely as all centres used the same
LGV targets and any circulating escape mutants should have
been detected at PHE where the majority of specimens were
tested.
Similar to the trend seen in the UK, between 2010 and 2016
increased LGV diagnoses were also reported in France, the
Netherlands, Belgium and the Republic of Ireland,6,26,27 and
both France and the Republic of Ireland saw a decrease in
diagnoses from 2016 to 201727 (C Bebear, pers. comm.),
whereas in the Netherlands, diagnoses increased by 11%
between 2016 and 2017.26 Despite a reduction in LGV
diagnoses, there is likely to be substantial underdiagnoses
of LGV across much of Europe, and testing coverage and
management need to be improved.28
In the UK, revisions to national management guidelines that
detail testing guidelines for LGV were made in response to
developments in our knowledge of the epidemic, including
increased insight into the burden of asymptomatic infection,
clinical presentation and groups at risk of infection. The scope
of LGV testing has been extended from performing LGV
testing only among patients with rectal symptoms to include
testing of those who were asymptomatic, recommending LGV
testing of samples from all MSM living with HIV who test
positive for C. trachomatis at any site12 and to focus testing on
those at highest risk of infection.
Changes in sexual health guidelines for MSM (2016),
which recommend quarterly STI screening of high-risk
MSM and the extension of LGV testing to include MSM
with positive rectal chlamydia, regardless of the presence of
LGV symptoms (2015), are likely to have contributed to the
national increase in LGV tests performed.25 From 2015, some
large London sexual health clinics that see a high throughput
of MSM and higher risk MSM initiated in-house testing for
LGV within their local laboratories, rather than referring
samples to the PHE National Reference Laboratory for
LGV testing. In some large London clinics, reflex testing,
that is, testing all samples positive for C. trachomatis for LGV
regardless of site of infection or risk group, is likely to have
had a substantial effect on the number of LGV tests performed,
especially where the patient was asymptomatic.
Despite higher annual diagnoses of LGV among
HIV-positive MSM compared with HIV-negative/untested
MSM up to 2015, the subsequent fall in LGV positivity
was greater in HIV-positive MSM, with almost equal
proportions of diagnoses among both groups seen in 2018.
This fall may be explained by increased disassortative sexual
mixing by HIV status and increased LGV testing within both
MSM groups, which may have extended the sexual network
considered at highest risk of LGV acquisition beyond that
detailed within the testing guidelines. This could be associated
with the increased, widespread availability of treatment for
prevention of HIV and pre-exposure prophylaxis..29,30
Additionally, reflex LGV testing in some London-based
clinics, which have developed in-house testing for LGV and
see a high throughput of MSM, may have increased testing of
MSM who do not fall within the testing criteria detailed in the
2015 guidance. This may have further improved LGV case
ascertainment.
Trends seen for LGV in the UK have not mirrored those
seen for gonorrhoea, syphilis and chlamydia, with the number
of individuals diagnosed with these STIs continuing to
increase.10 LGV is, however, less common and more
localised within specific risk groups and may therefore be
easier to control through targeted testing strategies.
A drop in LGV diagnoses may also have been influenced by
the switch in first-line treatment for chlamydia from 1 g single-
dose azithromycin to 7-days of 100 mg doxycycline. Single-
dose azithromycin was suggested to be less effective than
doxycycline for treating rectal C. trachomatis in MSM.31
Based on this evidence published in 2015, a change in
treatment regimen is likely to have been implemented
across several clinics in the UK before the update of the
national guidelines in 2018.22 As the revised treatment
regimen may be sufficient to treat very early asymptomatic
and undiagnosed LGV infection, by further reducing the pool
of asymptomatic LGV, this change may have acted as an
additional driver in the reduction in LGV diagnoses.
Additionally, the European Chlamydia management
guidelines were also updated in 2015 to recommend the use
of doxycycline as first-line treatment for chlamydia32 and the
fall in diagnoses seen in some European countries from 2015
may have been related to this change.
This investigation suggests that the changes in national
LGV and chlamydia management guidelines have had a
positive effect on the control of LGV infection, especially
among individuals considered at high risk of acquiring the
infection. As PHE seeks to reduce the burden of STIs in
England, it is encouraging to see the apparent public health
benefit of combined interventions. While the declining UK
trend is encouraging, there was some local variation, and
continued vigilance is important to identify any local
transmission clusters in areas where awareness of LGV may
be lower. Furthermore, it is unclear whether the recent drop in
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LGV diagnoses seen in the UK will be sustained over the
coming years or will follow a trajectory more in line with other
bacterial STIs. Further evaluation of the intervention strategies
and revisions to the management guidelines may be warranted
in the near future.
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